Search
Barinthus Biotherapeutics PLC
BRNSAdd to Watchlist
0.640USD
-0.020-3.02%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
26.15MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-3.02%
5 Days
-3.03%
1 Month
-5.96%
6 Months
-8.57%
Year to Date
-8.57%
1 Year
-28.88%
Key Figures
0.650Open
0.660High
37.17KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.09%Turnover Ratio
0.660Prev. Close
0.640Low
17.57KTurnover
LossP/E Static
0.39P/B
0.00%Div Yield TTM
-44.70%ROA
2.92052wk High
2.35Volume Ratio
-61.07MNet Profit
40.85MShares
-1.2865EPS TTM
-0.39Beta
-57.52%ROE
0.51252wk Low
3.14%Amplitude
100.00%Gross Margin
26.15MMarket Cap
--Reward/Risk
6.04%Risk Rate
TradingKey Stock Score of Barinthus Biotherapeutics PLC
Currency: USD Updated: 2026-06-30Key Insights
Barinthus Biotherapeutics PLC's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 185 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 5.50.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Barinthus Biotherapeutics PLC's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Barinthus Biotherapeutics PLC Highlights
StrengthsRisks
Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company focused on developing immunotherapeutic candidates for treating autoimmune and inflammatory diseases. The Company’s pipeline, built around platform technologies; viral vector-based, consists of ChAdOx and MVA, and synthetic, consisting of SNAP-Tolerance Immunotherapy (SNAP-TI). These platforms help to develop antigen-specific immunotherapeutic candidates designed to optimize the disease fighting capabilities of T cells. It is focused on developing two product candidates that harness its viral vector and synthetic platform technologies. These include VTP-300, a Phase II immunotherapeutic candidate designed as a potential component of a functional cure for chronic hepatitis B virus infection utilizing ChAdOx/MVA, and VTP-1000, its autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease. The Company's pipeline also includes VTP-850, VTP-500 and VTP-400.
Overvalued
The company’s latest PE is -0.51, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 16.70M shares, decreasing 10.42% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of -0.51.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
5.500
Target Price
+733.33%
Upside Space
Barinthus Biotherapeutics PLC News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Barinthus Biotherapeutics PLC Info
Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company focused on developing immunotherapeutic candidates for treating autoimmune and inflammatory diseases. The Company’s pipeline, built around platform technologies; viral vector-based, consists of ChAdOx and MVA, and synthetic, consisting of SNAP-Tolerance Immunotherapy (SNAP-TI). These platforms help to develop antigen-specific immunotherapeutic candidates designed to optimize the disease fighting capabilities of T cells. It is focused on developing two product candidates that harness its viral vector and synthetic platform technologies. These include VTP-300, a Phase II immunotherapeutic candidate designed as a potential component of a functional cure for chronic hepatitis B virus infection utilizing ChAdOx/MVA, and VTP-1000, its autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease. The Company's pipeline also includes VTP-850, VTP-500 and VTP-400.
Ticker SymbolBRNS
CompanyBarinthus Biotherapeutics PLC
CEOEnright (William J)
Websitehttps://www.barinthusbio.com/
Related Instruments
-0.64%
-0.05%
-2.95%
-0.23%
-2.41%
-1.64%
-0.22%
+1.75%
-0.29%
-0.79%
+0.26%
-2.00%
-2.10%
-2.41%
+1.68%
0.00%
+0.19%
-1.97%
+0.06%
-0.44%Popular Instruments
FAQs
What is the current price of Barinthus Biotherapeutics PLC (BRNS)?
The current price of Barinthus Biotherapeutics PLC (BRNS) is 0.64.
What is the symbol of Barinthus Biotherapeutics PLC?
The ticker symbol of Barinthus Biotherapeutics PLC is BRNS.
What is the 52-week high of Barinthus Biotherapeutics PLC?
The 52-week high of Barinthus Biotherapeutics PLC is 2.92.
What is the 52-week low of Barinthus Biotherapeutics PLC?
The 52-week low of Barinthus Biotherapeutics PLC is 0.51.
What is the market capitalization of Barinthus Biotherapeutics PLC?
The market capitalization of Barinthus Biotherapeutics PLC is 26.15M.
Is Barinthus Biotherapeutics PLC (BRNS) currently rated as Buy, Hold, or Sell?
According to analysts, Barinthus Biotherapeutics PLC (BRNS) has an overall rating of Buy, with a price target of 5.50.
What is the Earnings Per Share (EPS TTM) of Barinthus Biotherapeutics PLC (BRNS)?
The Earnings Per Share (EPS TTM) of Barinthus Biotherapeutics PLC (BRNS) is -1.64.